Document is current
Any future updates will be listed below
-
Authors
Bowley, Neil
Thomas, Peter
Sivaprasad, Sobha
Purbrick, Robert M. J.
Beardmore, Emily
Gilbert, Rose
Clarke, Andy
Chase, Thomas J. G. https://orcid.org/0000-0002-3445-7960
-
Funding
Funding for this research was provided by:
Bayer, plc
- License Information
-
More Information
Article History
Received: 8 May 2025
Revised: 4 September 2025
Accepted: 12 September 2025
First Online: 6 October 2025
Competing interests
: NB has received financial support from Alimera Sciences, Allergan, Bayer, Roche and Théa Pharmaceuticals. PT is co-founder and CEO of Cascader Ltd and has received financial support from Bayer and Haag-Streit. SS has received direct financial payment for attending advisory boards for AbbVie, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, EyePoint Pharmaceuticals, Iveric Bio, Janssen Pharmaceuticals, Kriya Therapeutics, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Ripple Therapeutics, Roche, Sanofi and Stealth BioTherapeutics; and has received travel and research grants from AbbVie, Apellis, Astellas, Bayer, Boehringer Ingelheim, Novo Nordisk and Roche. She is also the Editor-in-Chief of Eye. RMJP has received educational grants for conference attendance from Bayer and Roche, and payment for attending advisory boards for Roche. EB, RG, AC and TC are employees of Bayer plc, UK.
